Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells

Abstract

Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CSI or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

1 - 43 . (canceled) 
     
     
         44 . A purified immune cell for immunotherapy comprising:
 (a) an inactivated or mutated gene encoding a CS1 antigen marker; and   (b) a transgene encoding a chimeric antigen receptor (CAR) directed against said CS1 antigen marker.   
     
     
         45 . The immune cell according to  claim 44 , wherein said cell is purified by excluding cells presenting said CS1 antigen marker at their surface. 
     
     
         46 . The immune cell according to  claim 44 , wherein said cell is a primary cell. 
     
     
         47 . The immune cell according to  claim 44 , wherein said gene encoding a CS1 antigen marker is inactivated or mutated using a rare-cutting endonuclease. 
     
     
         48 . The immune cell according to  claim 47 , wherein the rare-cutting endonuclease is a TAL-nuclease. 
     
     
         49 . The immune cell according to  claim 44 , wherein said immune cell is a natural killer cell. 
     
     
         50 . The immune cell according to  claim 44 , wherein said immune cell is a T cell. 
     
     
         51 . The immune cell according to  claim 45 , wherein said immune cell is a T cell. 
     
     
         52 . The immune cell according to  claim 47 , wherein said immune cell is a T cell. 
     
     
         53 . The immune cell according to  claim 48 , wherein said immune cell is a T cell. 
     
     
         54 . The immune cell according to  claim 44 , wherein said gene encoding a CS1 antigen marker is an inactivated gene. 
     
     
         55 . The immune cell according to  claim 44 , wherein said gene encoding a CS1 antigen marker is a mutated gene. 
     
     
         56 . The immune cell according to  claim 44 , wherein a gene encoding a component of the T-cell receptor (TCR) is inactivated. 
     
     
         57 . The immune cell according to  claim 56 , wherein said component of the T-cell receptor is TCRα. 
     
     
         58 . the immune cell according to  claim 57 , wherein said immune cell is a T cell. 
     
     
         59 . A population of T cells comprising 10 4 -10 9  of the T cells of  claim 50 . 
     
     
         60 . A population of T cells comprising 10 4 -10 9  of the T cells of  claim 53 . 
     
     
         61 . A population of T cells comprising 10 4 -10 9  of the T cells of  claim 54 . 
     
     
         62 . A population of T cells comprising 10 4 -10 9  of the T cells of  claim 58 .